Merck & Co Inc logo

Merck & Co Inc

FRA:6MK (USA)  
€ 119.80 (+3.63%) Apr 22
898.43
P/B:
8.47
Market Cap:
€ 301.70B ($ 321.50B)
Enterprise V:
€ 327.94B ($ 349.46B)
Volume:
356.00
Avg Vol (2M):
441.00
Also Trade In:
Volume:
356.00
Avg Vol (2M):
441.00
PE Ratio PS Ratio PB Ratio Price-to-FCF Market Cap
Current and historical daily PE Ratio for Merck & Co Inc ( ) from 1990 to Apr 23 2024. The price to earnings ratio is calculated by taking the current stock price and dividing it by the most recent trailing twelve-month earnings per share (EPS) number. The data is updated every 20 minutes during market hours. The PE ratio can be viewed as the number of years it takes for the company to earn back the price you pay for the stock. Therefore, lower-P/E stocks are more attractive than higher P/E stocks so long as the PE ratio is positive. Also for stocks with the same PE ratio, the one with faster growth business is more attractive. Merck & stock (FRA:6MK) PE ratio as of Apr 23 2024 is 898.43. More Details

Merck & Co Inc (FRA:6MK) PE Ratio (TTM) Chart

To

Merck & Co Inc (FRA:6MK) PE Ratio (TTM) Historical Data

Total 1226
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 14
Merck & PE Ratio (TTM) Historical Data
Date PE Ratio (TTM) Data Date PE Ratio (TTM) Data
2024-04-23 700.6 2024-02-16 692.4
2024-04-22 700.6 2024-02-15 686.5
2024-04-19 676.0 2024-02-14 688.9
2024-04-18 685.4 2024-02-13 673.7
2024-04-17 691.2 2024-02-12 678.4
2024-04-16 693.6 2024-02-09 686.5
2024-04-15 688.9 2024-02-08 686.5
2024-04-12 691.2 2024-02-07 688.9
2024-04-11 685.4 2024-02-06 692.4
2024-04-10 687.7 2024-02-05 690.1
2024-04-09 676.0 2024-02-02 687.7
2024-04-08 683.0 2024-02-01 670.2
2024-04-05 691.2 2024-01-31 655.0
2024-04-04 691.2 2024-01-30 649.1
2024-04-03 714.6 2024-01-29 653.8
2024-04-02 705.3 2024-01-26 651.5
2024-03-28 717.0 2024-01-25 648.0
2024-03-27 712.3 2024-01-24 639.8
2024-03-26 676.0 2024-01-23 645.6
2024-03-25 673.7 2024-01-22 643.3
2024-03-22 669.0 2024-01-19 637.4
2024-03-21 664.3 2024-01-18 639.8
2024-03-20 656.1 2024-01-17 639.8
2024-03-19 656.1 2024-01-16 637.4
2024-03-18 655.0 2024-01-12 631.6
2024-03-15 646.8 2024-01-11 631.6
2024-03-14 643.3 2024-01-10 633.9
2024-03-13 650.3 2024-01-09 635.1
2024-03-12 658.5 2024-01-08 625.7
2024-03-11 655.0 2024-01-05 628.1
2024-03-08 663.2 2024-01-04 624.6
2024-03-07 663.2 2024-01-03 617.5
2024-03-06 660.8 2024-01-02 602.3
2024-03-05 666.7 2023-12-29 574.9
2024-03-04 665.5 2023-12-28 576.6
2024-03-01 688.9 2023-12-27 56.4
2024-02-29 691.2 2023-12-22 56.6
2024-02-28 690.1 2023-12-21 55.9
2024-02-27 694.7 2023-12-20 55.9
2024-02-26 695.9 2023-12-19 56.1
2024-02-23 701.8 2023-12-18 55.9
2024-02-22 692.4 2023-12-15 56.0
2024-02-21 688.9 2023-12-14 55.6
2024-02-20 692.4 2023-12-13 56.6
2024-02-19 686.5 2023-12-12 56.1

Merck & Co Inc (FRA:6MK) PE Ratio (TTM) Comparison

Company Market Cap(Mil) PE Ratio (TTM)

Business Description

Business Description

Description
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent pediatric diseases as well as human papillomavirus, or HPV. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the company's sales are generated in the United States.